Senior Editor: Alan Agbele
Nearly two-thirds of US doctors now consult an AI-powered search engine before making patient decisions, a shift that has pushed a little-known Miami startup to a $15 billion valuation.
OpenEvidence, founded in 2022 by serial entrepreneur Daniel Nadler, said America's roughly 1 million physicians processed more than 42 million prompts last month. Doctors use the chatbot to scan medical journals and clinical guidelines for diagnosis and treatment support.
How OpenEvidence Reached Clinical Scale
OpenEvidence did not follow the usual path into hospitals. Most healthcare software reaches physicians through institutional procurement, lengthy pilots and compliance reviews. This platform instead spread directly between individual Doctors.
Daniel Nadler, the founder, described the pattern in blunt terms. "We're the first viral consumer internet app in healthcare," he told the Financial Times.
That framing matters because it suggests the adoption curve resembles a social product more than a medical device. Physicians share tools with colleagues when they find them useful, and OpenEvidence appears to have benefited from that dynamic.
Why This Matters
The immediate consequence is that a private company now sits between Doctors and the medical evidence they rely on. If OpenEvidence's answers shape diagnosis or treatment choices, its ranking and retrieval systems become part of clinical infrastructure, whether or not regulators treat them that way.
Advertising introduces a second layer of risk. An ad-supported model must eventually reconcile commercial incentives with clinical neutrality. Doctors, hospitals and malpractice insurers will want to know whether sponsored content can influence what a physician sees at the point of care.
The $15 billion valuation also signals that investors expect healthcare AI to monetize at consumer internet speed. That expectation will pressure OpenEvidence to expand aggressively, potentially into markets where medical liability rules differ sharply from those in the United States.
The Advertising Question in Clinical Settings
OpenEvidence generates revenue through advertising rather than subscriptions or institutional licenses. That choice lowers the barrier for individual Doctors but creates a structural tension.
Medical evidence is supposed to be ranked by relevance and rigor, not by willingness to pay. If advertisers can target physicians by specialty or query intent, the line between information and promotion becomes harder to police.
Comparable consumer platforms have faced similar scrutiny. Search engines and social networks have spent years defending the separation of organic results from paid placements. Healthcare raises the stakes because the end user is making decisions that affect patient safety.
What You Need to Know About the Market Shift
The broader trend is the arrival of AI tools that bypass traditional healthcare IT gatekeepers. Electronic health record vendors, hospital systems and insurers have long controlled which software reaches physicians. A viral product that spreads peer to peer weakens that control.
Several factors explain why this matters beyond OpenEvidence itself.
Each of these factors will shape whether OpenEvidence becomes a durable clinical standard or a cautionary tale about scaling too quickly in a regulated field.
What Comes Next for Physicians and Investors
Doctors who already use the platform face a practical question. They must decide how much weight to give AI-generated summaries when their own clinical judgment and professional liability are on the line.
Investors, meanwhile, are betting that OpenEvidence can convert viral adoption into a defensible business. That bet depends on whether advertising can fund the platform without eroding the trust that made it spread in the first place.
The company's next moves, including any expansion beyond US physicians, will test whether consumer-style growth is compatible with the standards that govern medical practice.
